Background and Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by the accumulation of fat in the liver, progressing from simple steatosis to various complications, with increasing prevalence in the modern world. Our study aimed to investigate the relationship between MASLD pathogenesis and the presence of apolipoprotein C-III (ApoC-III) gene variants rs2854116 and rs2854117 by comparing allele and genotype frequencies between MASLD patients and healthy individuals, as well as analyzing their association with biochemical parameters in Turkish populations. Materials and Methods: The study included 202 MASLD patients and 100 healthy controls who presented to our outpatient clinic. MASLD presence was determined by ultrasonography (USG). The demographic, laboratory, and clinical data of the participants were recorded. ApoC-III gene variants rs2854116 and rs2854117 were genotyped using the Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) method from genomic DNA samples obtained from blood. Results: The genotype and allele frequencies of ApoC-III gene variants rs2854116 and rs2854117 did not show significant differences between patient and healthy groups (p > 0.05). When biochemical parameters were evaluated, the LDH value of rs2854116 variant CT/CC genotype carriers was found to be significantly higher than TT genotype carriers (p = 0.016). Conclusions: We observed a high prevalence of MASLD in our Turkish cohort. However, the specific genetic variants we investigated were not associated with MASLD status. This suggests that these variants may not be significant contributing factors to MASLD in this population.

Background and Aims: The age‐at‐onset is of great importance in the heterogeneity of Type 1 diabetes mellitus (T1DM). This study was designed to define clinical and laboratory differences between child–adolescent‐onset and adult‐onset T1DM at presentation and during follow‐up and determine the predicting factors for developing microvascular and macrovascular complications. Material and Methods: This retrospective observational study evaluated T1DM patients who were followed in the diabetes outpatient clinic between January 1, 2000, and December 31, 2019. Results: The study cohort included 490 individuals with T1DM (54.3% female, 58.8% adult‐onset, and median follow‐up: 5 years). In the adult‐onset group, baseline C‐peptide and GADA prevalence were higher, whereas presentation with ketoacidosis was 2.3‐fold lower compared to the child–adolescent‐onset group ( p < 0.001). During follow‐up, the adult‐onset group had a 2.4‐fold higher overweight/obesity ( p < 0.001) and 1.7‐fold higher dyslipidemia/hyperlipidemia ( p = 0.002) than the child–adolescent‐onset group. In multivariate analysis, fasting glucose ( p = 0.024) in adult‐onset, dyslipidemia/hyperlipidemia ( p = 0.037) in child–adolescent‐onset, and diabetes duration ( p = 0.008 and p = 0.007) and hypertension ( p = 0.001 and p = 0.01) in both groups were associated with increased risk of microvascular complications, whereas age‐at‐onset ( p = 0.024), dyslipidemia/hyperlipidemia ( p = 0.03), nephropathy ( p = 0.003), and neuropathy ( p = 0.001) in adult‐onset and age ( p = 0.002) and triglycerides ( p = 0.013) in child–adolescent‐onset groups were associated with increased risk of macrovascular complications. The cutoff C‐peptide levels at baseline predicted microvascular complications in the whole cohort and adult‐onset group were defined as 0.383 ng/mL ( p < 0.001) and 0.41 ng/mL ( p = 0.001), respectively. In the Kaplan–Meier analysis, C‐peptide (< 0.383 ng/mL) but not age‐at‐onset predicted future development of microvascular and macrovascular complications ( p = 0.003 and p = 0.032). Conclusion: Clinical presentation and prognosis differ in adult‐onset and child–adolescent‐onset T1DM. Low initial C‐peptide may predict the development of microvascular and macrovascular complications.